LEXINGTON, Mass.--(BUSINESS WIRE)--Dec. 6, 2017--
Quanterix
Corporation, a company with a next generation, ultra-sensitive
digital platform that advances precision health, today announced the
pricing of its initial public offering of 4,275,200 shares of its common
stock at a public offering price of $15.00 per share for aggregate gross
proceeds of $64,128,000. In addition, Quanterix has granted the
underwriters a 30-day option to purchase up to 641,280 additional shares
of common stock at the initial public offering price, less the
underwriting discount. The shares are scheduled to begin trading on
The Nasdaq Global Market under the ticker symbol “QTRX” on December 7,
2017, and the offering is expected to close on December 11, 2017,
subject to customary closing conditions.
J.P. Morgan Securities LLC, Leerink Partners LLC and Cowen and Company,
LLC are serving as joint book-running managers for the offering. BTIG,
LLC and Evercore Group L.L.C. are serving as co-managers.
A registration statement relating to these securities was declared
effective by the Securities and Exchange Commission on December 6, 2017.
The offering will be made only by means of a prospectus. A copy of the
final prospectus related to the offering will be filed with the
Securities and Exchange Commission and may be obtained, when available,
from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions,
1155 Long Island Avenue, Edgewood, NY 11717, telephone: (866) 803-9204;
Leerink Partners LLC, Attention: Syndicate Department, One Federal
Street, 37th Floor, Boston, MA 02110, by telephone at (800) 808-7525,
ext. 6132 or by email at syndicate@leerink.com;
or Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155 Long
Island Avenue, Edgewood, NY 11717, Attn: Prospectus Department, or by
calling (631) 274-2806 or by faxing (631) 254-7140.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of, these
securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification of these securities under the securities laws of any such
state or jurisdiction.
Forward-Looking Statements
This press release contains
certain forward-looking statements, including statements with regard to
Quanterix Corporation’s proposed initial public offering. Words such as
“expects,” “anticipates” and “intends” or similar expressions are
intended to identify forward-looking statements. These forward-looking
statements are subject to the inherent uncertainties in predicting
future results and conditions and no assurance can be given that the
initial public offering discussed above will be completed on the terms
described. Completion of the proposed initial public offering and the
terms thereof are subject to numerous factors, many of which are beyond
the control of the Company, including, without limitation, failure of
customary closing conditions and the risk factors and other matters set
forth in the prospectus included in the registration statement, in the
form last filed with the Commission. Quanterix undertakes no obligation
to publicly update or revise any forward-looking statements, whether as
a result of new information, future events or otherwise, except as may
be required by law.
About Quanterix
Quanterix is a company digitizing biomarker
analysis with the goal of advancing the science of precision health. The
company’s digital health solution, Simoa, has the potential to change
the way in which healthcare is provided today by giving researchers the
ability to closely examine the continuum from health to disease.
Quanterix’ technology is designed to enable much earlier disease
detection, better prognoses and enhanced treatment methods to improve
the quality of life and longevity of the population for generations to
come. The technology is currently being used for research applications
in several therapeutic areas, including oncology, neurology, cardiology,
inflammation and infectious disease. The company was established in 2007
and is located in Lexington, Massachusetts.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171206006455/en/
Source: Quanterix Corporation
Quanterix PR Contact:
PAN Communications
Lauren
Kaufman, 617-502-4300
quanterix@pancomm.com
or
Quanterix
IR Contact:
Joe Driscoll, 617-301-9400
Chief Financial
Officer
jdriscoll@quanterix.com